Osborne Partners Capital Management, LLC Biogen Inc. Transaction History

Osborne Partners Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 22, 2024	BUY	$190.52 - $236.72 $176,231 - $218,966	925 New	925 $214,000
Q3 2022 Oct 27, 2022	BUY	$194.69 - $268.46 $180,088 - $248,325	925 New	925 $247,000
Q1 2022 May 05, 2022	SELL	$193.77 - $244.14 $179,237 - $225,829	-925 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$259.0 - $414.71 $6,475 - $10,367	-25 Reduced 2.63%	925 $320,000
Q1 2021 Apr 27, 2021	SELL	$242.95 - $284.63 $121,475 - $142,315	-500 Reduced 34.48%	950 $266,000
Q2 2020 Jul 23, 2020	SELL	$258.66 - $342.55 $33,625 - $44,531	-130 Reduced 8.23%	1,450 $388,000
Q3 2018 Oct 26, 2018	SELL	$293.51 - $383.83 $11,740 - $15,353	-40 Reduced 2.47%	1,580 $558,000
Q2 2018 Jul 19, 2018	SELL	$257.52 - $306.91 $9,013 - $10,741	-35 Reduced 2.11%	1,620 $470,000
Q1 2018 Apr 19, 2018	SELL	$260.13 - $367.91 $2,341 - $3,311	-9 Reduced 0.54%	1,655 $453,000
Q4 2017 Jan 25, 2018	SELL	$307.64 - $344.58 $8,921 - $9,992	-29 Reduced 1.71%	1,664 $530,000
Q3 2017 Oct 19, 2017	BUY	$281.15 - $329.69 $475,986 - $558,165	1,693	1,693 $530,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Osborne Partners Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Osborne Partners Capital Management, LLC with notifications on news.